IDEXX's 0.02% Rally on $300M Volume Hits 343rd in Activity Amid Insider Transactions

On August 12, 2025, IDEXX Laboratories (IDXX) saw a 0.02% rise in its stock price, with a trading volume of $300 million, ranking 343rd in daily market activity. Two insider transactions were disclosed via SEC Form 4 filings, impacting investor sentiment.

Jonathan Jay Mazelsky, IDEXX’s CEO and director, exercised a Premium Incentive Stock Option on August 8, acquiring 183 shares at $598.488 each. Post-transaction, he retained direct ownership of 83,494.3016 shares. The option, granted at a 110% premium to the 2021 closing price, became exercisable on February 14, 2025. Analysts noted this as routine executive compensation activity with no indication of liquidity events or governance concerns.

Separately, Sharon E. Underberg, the company’s EVP and General Counsel, reported simultaneous buy-and-sell transactions on August 8. She acquired 5,450 shares at $206.94 and disposed of an equal number at $651.60. A subsequent acquisition of 183 shares on August 12 brought her net beneficial ownership to 6,338.6539 shares. The filing also detailed 28.7090 shares purchased via the Employee Stock Purchase Plan in 2025. Derivative holdings included a non-qualified option for 5,450 shares and an incentive option for 183 shares, both with stated exercise prices.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day yielded a $2,300 profit from 2022 to the present, with a maximum drawdown of -15.7% in early 2023. This highlights the strategy’s moderate returns amid market volatility.